Renal Cancer - Results from #1540

Advances in Renal Cell Carcinoma Drug Resistance Models. May 30, 2022

Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. May 30, 2022

[The prognostic value of preoperative neutrophil-to-lymphocyte ratio in patients with non-metastatic renal cell carcinoma]. May 27, 2022

Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab. May 27, 2022

Histologic diversity in chromophobe renal cell carcinoma does not impact survival outcome: A comparative international multi-institutional study. May 26, 2022

Oncological outcomes of retroperitoneal lymph node dissection during retroperitoneal laparoscopic radical nephroureterectomy for renal pelvic or upper ureteral tumors: Matched-pair analysis. May 26, 2022

NCAPG Promotes the Proliferation of Renal Clear Cell Carcinoma via Mediating with CDK1. May 25, 2022

Which factors can influence post-operative renal function preservation after nephron-sparing surgery for kidney cancer: a critical review. May 25, 2022

Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy. May 24, 2022

Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: the CABIR study. May 24, 2022

Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents. May 23, 2022

The WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. May 23, 2022

Impact of the Discordance Between Scales of Memorial Sloan-Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium in Patients' Prognosis With Metastatic Renal Cancer. May 20, 2022

Glutaminase inhibition in renal cell carcinoma therapy. May 20, 2022

A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma. May 19, 2022

Artificial Intelligence in Kidney Cancer. May 19, 2022

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial. May 18, 2022

Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. May 18, 2022

A Novel Machine Learning 13-Gene Signature: Improving Risk Analysis and Survival Prediction for Clear Cell Renal Cell Carcinoma Patients. May 17, 2022

Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. May 17, 2022

Page 78 of 459